Bipolar Affective Disorder

1. Topic Overview

Summary

Bipolar Affective Disorder (BPAD) is a chronic, recurrent mood disorder characterised by episodes of mania or hypomania alternating with episodes of major depression. The condition represents one of the leading causes of disability worldwide, affecting approximately 1-2% of the global population with lifetime prevalence rates of 0.6% for Bipolar I and 0.4-1% for Bipolar II disorder. [1,2]

The disorder typically manifests in late adolescence or early adulthood, with a mean age of onset between 20-25 years. BPAD carries substantial morbidity and mortality, with standardised mortality ratios approximately 2-3 times higher than the general population, largely attributable to cardiovascular disease and suicide. The suicide attempt rate approaches 25-50% over the lifetime, with completed suicide occurring in 15-20% of untreated patients. [1,3]

Bipolar I disorder is defined by the occurrence of at least one manic episode, whilst Bipolar II requires hypomanic episodes with major depressive episodes. The distinction has important prognostic and therapeutic implications. Current evidence strongly supports lithium as the gold standard for long-term prophylaxis, particularly for prevention of manic relapse and reduction of suicide risk. [3,4]

Key Facts

Clinical Pearls

High-Yield Examination Points:

• NEVER give antidepressant monotherapy in bipolar disorder - risk of manic switch is 20-40% and may induce rapid cycling [3,4]
• Lithium remains gold standard for long-term prophylaxis - reduces suicide risk by 60-80%, unique amongst mood stabilisers [3,5]
• Valproate is absolutely contraindicated in women of childbearing potential due to severe teratogenicity (neural tube defects, developmental delay) [4,6]
• Lamotrigine is particularly effective for bipolar depression prophylaxis but requires very slow titration (risk of Stevens-Johnson syndrome) [4,7]
• Quetiapine has strongest evidence for acute bipolar depression and is now first-line in many guidelines [4,8]
• Mixed states (mania + depressive features simultaneously) carry highest suicide risk and require urgent intervention
• First presentation of "depression" in young person (age less than 25) - always screen for bipolar (MDQ, past hypomanic symptoms)
• Rapid cycling (≥4 episodes/year) predicts poorer response to lithium; consider valproate or atypical antipsychotics [4,9]

Why This Matters Clinically

Bipolar disorder is frequently misdiagnosed, with studies suggesting up to 40% of patients initially receive a diagnosis of unipolar depression. This diagnostic delay averages 5-10 years and has profound implications - antidepressant monotherapy in unrecognised bipolar disorder significantly increases the risk of manic switch, cycle acceleration, and mixed states. [1,2]

Correct early diagnosis enables appropriate mood stabiliser initiation, substantially reducing morbidity, mortality, and healthcare costs. The BALANCE trial demonstrated lithium monotherapy superior to valproate for long-term relapse prevention, whilst modern guidelines emphasise individualised treatment selection based on predominant polarity (manic vs depressive), comorbidities, and patient factors. [3,4,5]

---

2. Epidemiology

Prevalence and Incidence

Secular Trends

The apparent increase in bipolar disorder diagnoses over recent decades reflects improved recognition, expanded diagnostic criteria (including Bipolar II), and possibly genuine increases related to environmental factors. Childhood-onset bipolar disorder remains controversial, with significant diagnostic overlap with ADHD and disruptive behaviour disorders.

Risk Factors

Genetic Factors (Strongest Predictive Value):

Associated Genetic Loci:

• CACNA1C (voltage-gated calcium channel)
• ANK3 (ankyrin 3)
• ODZ4 (teneurin transmembrane protein)
• NCAN (neurocan)
• Multiple overlapping loci with schizophrenia and major depression

Environmental Risk Factors:

Comorbidities

Bipolar disorder exhibits exceptionally high rates of psychiatric and medical comorbidity, significantly impacting prognosis and treatment:

---

3. Pathophysiology

Neurobiological Models

Bipolar disorder pathophysiology involves complex interactions between genetic vulnerability, neurochemical imbalances, circadian rhythm disruption, neuroinflammation, and structural brain changes. [1,10]

Monoamine Hypothesis

Mania:

• Elevated dopaminergic neurotransmission, particularly in mesolimbic pathways
• Increased noradrenergic activity
• Relative serotonin excess in some circuits

Depression:

• Reduced serotonergic, noradrenergic, and dopaminergic neurotransmission
• Decreased monoamine oxidase A (MAO-A) binding in some brain regions
• Impaired neuroplasticity signalling

Second Messenger and Intracellular Signalling

Circadian Rhythm Dysfunction

Circadian abnormalities are central to bipolar pathophysiology and treatment: [1,10]

• Clock Gene Polymorphisms: Variants in CLOCK, ARNTL, PER3, CRY genes associated with bipolar disorder
• Melatonin Dysregulation: Abnormal melatonin secretion patterns, reduced amplitude
• Sleep-Wake Cycle: Sleep deprivation can trigger mania within 24-48 hours
• Social Rhythms: Disruption of daily routines precipitates episodes
• Light Sensitivity: Altered sensitivity may underlie seasonal patterns

Neuroinflammation and Immune Dysregulation

Mitochondrial Dysfunction

Emerging evidence supports mitochondrial dysfunction as a core pathophysiological mechanism: [1,10]

• Decreased mitochondrial respiratory chain enzyme activity
• Reduced ATP production in neurons
• Increased oxidative stress and reactive oxygen species
• Calcium signalling abnormalities
• Genetic associations with mitochondrial genes
• Explains the progressive nature and cognitive decline

Structural and Functional Neuroimaging

Kindling Hypothesis

The kindling model proposes that: [1]

1. Early episodes are typically triggered by major life stressors
2. Successive episodes require progressively less provocation
3. Eventually, episodes occur spontaneously without identifiable triggers
4. Neurobiological sensitisation underlies this progression
5. Early and sustained treatment may prevent kindling

This model supports the importance of early diagnosis and continuous prophylactic treatment to prevent episode recurrence and progressive deterioration.

Staging Model

---

4. Clinical Presentation

Bipolar I vs Bipolar II Comparison

Mania (Bipolar I Defining Feature)

DSM-5 Criteria:

• Distinct period of abnormally elevated, expansive, or irritable mood AND increased goal-directed activity/energy
• Duration: ≥7 days (or any duration if hospitalisation required)
• Plus ≥3 of the following (4 if mood only irritable):

DIGFAST Mnemonic:

Severity Specifiers:

• Mild: Minimum symptoms, minor functional impairment
• Moderate: Increased symptoms, moderate impairment
• Severe: Multiple symptoms, marked impairment, may need supervision
• With Psychotic Features: Mood-congruent or incongruent delusions/hallucinations

Manic Psychosis Features:

Hypomania (Bipolar II Defining Feature)

DSM-5 Criteria:

• Same mood and symptom criteria as mania
• Duration: ≥4 consecutive days
• Unequivocal change in functioning observable by others
• NOT severe enough to cause marked impairment or require hospitalisation
• NO psychotic features (if present, diagnosis is mania)

Distinguishing Hypomania from Mania:

Major Depressive Episodes

Depressive episodes in bipolar disorder are often clinically indistinguishable from unipolar depression but may exhibit distinctive features: [1,2]

Core Symptoms (Same as MDD):

• Depressed mood most of the day, nearly every day
• Anhedonia (loss of interest/pleasure)
• Weight/appetite changes
• Insomnia or hypersomnia
• Psychomotor agitation or retardation
• Fatigue/loss of energy
• Worthlessness/excessive guilt
• Concentration difficulties
• Suicidal ideation

Features Suggestive of Bipolar Depression:

Mixed Features Specifier

Mixed states represent a high-risk clinical presentation requiring urgent attention: [1,3]

Definition: Full criteria for manic/hypomanic episode PLUS ≥3 depressive symptoms, OR full criteria for depressive episode PLUS ≥3 manic/hypomanic symptoms

Clinical Features:

• Dysphoric mania: Irritable, agitated, with depressive cognitions
• Depressive mixed: Low mood with racing thoughts, increased energy
• Marked psychomotor agitation
• Severe anxiety
• Extreme emotional lability

Risk Profile:

• Highest suicide risk of all bipolar presentations
• Poor response to standard treatments
• Antidepressants contraindicated (worsen mixed states)
• Requires mood stabiliser + atypical antipsychotic
• Often requires inpatient care

Rapid Cycling Specifier

Definition: ≥4 mood episodes (manic, hypomanic, or depressive) within 12 months [1,4,9]

---

5. Clinical Examination

Mental State Examination - Manic Phase

Mental State Examination - Depressive Phase

Risk Assessment Framework

Manic Phase Risks:

Depressive/Mixed Phase Risks:

High-Risk Periods for Suicide:

• Transition from mania to depression
• Mixed affective states
• Early recovery phase
• Medication non-adherence
• Recent discharge from hospital
• Substance intoxication/withdrawal

---

6. Investigations

Diagnostic Workup

Initial Assessment (All Patients):

Additional Investigations (If Indicated):

Rating Scales and Screening Tools

Screening:

Severity Assessment:

Differential Diagnosis

Psychiatric Differentials:

Organic Differentials:

---

7. Classification

DSM-5 Bipolar and Related Disorders

Episode Specifiers

Course Specifiers:

• With anxious distress
• With mixed features
• With rapid cycling
• With melancholic features (depression)
• With atypical features (depression)
• With mood-congruent psychotic features
• With mood-incongruent psychotic features
• With catatonia
• With peripartum onset
• With seasonal pattern

Severity/Remission:

• Mild, Moderate, Severe
• In partial remission
• In full remission

Predominant Polarity

Identifying predominant polarity guides treatment selection: [4]

---

8. Management

Principles of Bipolar Treatment

1. Accurate diagnosis - rule out organic causes, confirm polarity
2. Risk assessment - suicide, aggression, functional impairment
3. Acute treatment - stabilise current episode
4. Maintenance treatment - prevent recurrence
5. Address comorbidities - substance use, anxiety, metabolic
6. Psychoeducation - patient and family/carers
7. Psychosocial interventions - therapy, lifestyle, support
8. Regular monitoring - efficacy, side effects, physical health

Acute Mania Treatment

First-Line Options (NICE, BAP, CANMAT Guidelines): [4,6]

Discontinue:

• Antidepressants (can fuel mania)

Combination Approaches:

• Antipsychotic + lithium or valproate for severe/refractory cases
• Superior to monotherapy in systematic reviews

Setting:

• Mild: Intensive community treatment
• Moderate-Severe: Inpatient admission
• Consider Mental Health Act if lacks capacity/insight and at risk

Acute Bipolar Depression Treatment

First-Line Options: [4,8]

Second-Line:

• Add antidepressant to mood stabiliser (with caution)
• ECT for severe/treatment-resistant cases

AVOID:

• Antidepressant monotherapy - 20-40% switch rate to mania [3,4]
• Tricyclics - highest switch rate
• SSRIs/SNRIs safer but still require mood stabiliser cover

Maintenance (Prophylactic) Treatment

First-Line Mood Stabilisers: [3,4,5,7]

Atypical Antipsychotics with Maintenance Indication:

Lithium - The Gold Standard

BALANCE Trial Evidence (2010): [3]

• Lithium monotherapy superior to valproate monotherapy for relapse prevention
• Combination lithium + valproate not clearly superior to lithium alone
• Lithium remains gold standard for long-term prophylaxis

Unique Benefits of Lithium:

• Anti-suicidal effect: 60-80% reduction in suicide risk [5]
• Neuroprotective properties: Increased grey matter volume
• Anti-inflammatory effects
• Circadian rhythm stabilisation

Lithium Initiation and Monitoring:

Lithium Side Effects:

Lithium Toxicity:

Precipitants of Toxicity:

• Dehydration (vomiting, diarrhoea, heat, fever)
• Renal impairment
• Drug interactions: NSAIDs, ACE inhibitors, diuretics (thiazide > loop)
• Deliberately increased dose

Valproate Considerations

Efficacy: [4,6]

• Effective for acute mania and prophylaxis of manic episodes
• Less effective than lithium for suicide prevention
• Useful in rapid cycling, mixed states

CRITICAL: Teratogenicity - Valproate Pregnancy Prevention Programme:

• Neural tube defects: 1-2% risk (10x increase)
• Developmental delay: 30-40% of exposed children
• Lower IQ: Mean 10-point reduction
• MHRA/FDA: Contraindicated in women of childbearing potential unless Pregnancy Prevention Programme followed
• Requires highly effective contraception and annual review

Lamotrigine for Bipolar Depression

Evidence: [4,7]

• Primarily effective for depressive episode prevention
• Limited efficacy for acute depression or manic prevention
• Well-tolerated, weight-neutral
• No routine blood monitoring required

Titration Schedule (Essential):

If taking valproate: Halve all doses (valproate inhibits lamotrigine metabolism)

Stevens-Johnson Syndrome Risk:

• ~0.1% incidence (1 in 1000)
• Higher with rapid titration
• Stop immediately if rash develops, especially with systemic symptoms

Quetiapine in Bipolar Disorder

Evidence: [4,8]

• Strong RCT evidence for acute bipolar depression (BOLDER studies)
• Effective for acute mania (high doses)
• Approved for maintenance treatment
• Effective as monotherapy or adjunct

Dosing:

• Bipolar depression: 300-600 mg/day (extended release)
• Mania: 400-800 mg/day
• Maintenance: 300-800 mg/day

Side Effects:

• Sedation (common, often useful for insomnia)
• Orthostatic hypotension
• Weight gain, metabolic syndrome
• QTc prolongation (dose-dependent)

Rapid Cycling Management

Key Principles: [4,9]

1. Discontinue antidepressants - may be perpetuating cycling
2. Optimise thyroid function - treat subclinical hypothyroidism
3. Address substance use - alcohol, cannabis
4. Stabilise sleep - circadian rhythm interventions

Pharmacological Approach:

• Lithium less effective but still first-line
• Valproate may be preferred
• Lamotrigine for depressive pole
• Consider atypical antipsychotics
• Combination therapy often needed

Treatment-Resistant Bipolar Disorder

Definition: Inadequate response to ≥2 adequate trials of different mood stabilisers

Strategies:

1. Ensure adequate dose and duration of current treatment
2. Check adherence (plasma levels)
3. Optimise comorbidities (substance use, thyroid, sleep)
4. Combination therapy (lithium + valproate, lithium + antipsychotic)
5. Clozapine (limited evidence but useful in refractory cases)
6. ECT (effective for severe depression, mania, catatonia)
7. Adjunctive treatments (T3/T4, omega-3, NAC)

Electroconvulsive Therapy (ECT)

Indications in Bipolar Disorder:

• Severe depression with psychotic features
• Treatment-resistant depression
• Severe mania (especially if catatonic features)
• Mixed states with high suicide risk
• Life-threatening food/fluid refusal
• Pregnancy (safer than medications)

Efficacy:

• Response rates 50-70% in treatment-resistant cases
• Faster onset than medications
• May require maintenance ECT for relapse prevention

Psychological Therapies

Evidence-Based Interventions: [4]

Psychotherapy Reduces:

• Relapse rates (30-50% reduction)
• Hospital admissions
• Medication non-adherence
• Functional impairment

Lifestyle and Self-Management

---

9. Special Populations

Bipolar Disorder in Pregnancy

Key Considerations:

• 100-fold increased risk of postpartum psychosis
• Medication decisions balance teratogenicity vs relapse risk
• Untreated illness also risks foetus (stress hormones, poor self-care)

Medication Risk Categories:

Postpartum Management:

• Highest risk period for relapse
• Consider prophylactic lithium postpartum
• Close monitoring first 3 months
• Breastfeeding decisions individualised

Paediatric Bipolar Disorder

Controversies:

• Significant diagnostic uncertainty before puberty
• Overlap with ADHD, disruptive mood dysregulation disorder (DMDD)
• Irritability may be more prominent than euphoria

Treatment:

• Similar medications but with more caution
• Greater focus on psychosocial interventions
• Family therapy essential
• Careful metabolic monitoring

Elderly Patients

Considerations:

• New-onset mania warrants organic workup
• Increased sensitivity to medications
• Higher risk lithium toxicity (reduced renal function)
• More comorbidities and drug interactions
• Cognitive impairment may complicate picture

---

10. Complications

Acute Complications

Chronic Complications

---

11. Prognosis

Natural History

Prognostic Factors

Poor Prognosis:

• Early age of onset
• Rapid cycling pattern
• Mixed episodes
• Psychotic features
• Comorbid substance use
• Comorbid personality disorder
• Poor medication adherence
• High expressed emotion in family
• Multiple prior episodes
• Longer duration of illness before treatment

Good Prognosis:

• Later age of onset
• Few prior episodes
• Good inter-episode functioning
• Good insight
• Lithium responsiveness
• Strong social support
• Good medication adherence
• Absence of substance use

Mortality

---

12. Evidence and Guidelines

Key Guidelines

Landmark Trials

---

13. Patient/Layperson Explanation

What is Bipolar Disorder?

Bipolar disorder is a condition that causes extreme mood swings - periods of feeling abnormally "high" and energetic (called mania or hypomania) alternating with periods of feeling very low and depressed. These mood episodes are much more intense than normal ups and downs, and they last for days to weeks rather than hours.

About 1-2 in every 100 people have bipolar disorder. It usually begins in the late teenage years or early twenties, though it can start at any age.

What are the Types?

Bipolar I: You experience full manic episodes (extremely elevated mood, high energy, reduced sleep, impulsive behaviour) that last at least a week. Depressive episodes also occur but aren't required for diagnosis.

Bipolar II: You have hypomanic episodes (a less intense form of mania lasting at least 4 days) plus depressive episodes. People with Bipolar II often spend more time depressed.

What are the Symptoms?

During a Manic Episode:

• Feeling extremely energetic, euphoric, or very irritable
• Sleeping very little (maybe 2-3 hours) but feeling full of energy
• Racing thoughts and talking very fast
• Making impulsive decisions (spending money you don't have, risky sexual behaviour)
• Feeling invincible or having grand ideas about yourself
• Being easily distracted
• Taking on many projects at once

During a Depressive Episode:

• Feeling very low, empty, or hopeless
• Having no energy or motivation
• Sleeping too much or too little
• Changes in appetite (eating much more or much less)
• Difficulty concentrating or making decisions
• Thoughts of death or suicide

What Causes It?

Bipolar disorder results from a combination of factors:

• Genetics: It runs strongly in families (70-90% heritable)
• Brain chemistry: Imbalances in brain chemicals like dopamine and serotonin
• Life events: Stress can trigger episodes, especially early in the illness
• Sleep disruption: Disturbed sleep can trigger mania

How is it Treated?

Medications:

• Mood stabilisers (especially lithium) are the main treatment - they help even out mood swings and prevent future episodes
• Antipsychotic medications can help during manic episodes and sometimes depression
• Antidepressants are used carefully and almost never alone (they can trigger mania)

Talking therapies:

• Help you understand your illness and recognise early warning signs
• Improve coping strategies
• Address relationship and work problems

Lifestyle:

• Keeping a regular sleep schedule is very important
• Avoiding alcohol and recreational drugs
• Monitoring your mood daily
• Having an action plan for early warning signs

Is it Treatable?

Yes. While bipolar disorder is a lifelong condition, most people can manage it well with treatment. Staying on medication long-term is usually necessary - stopping medication is the most common cause of relapse.

With proper treatment, many people with bipolar disorder lead full, productive lives. Early diagnosis and consistent treatment are key.

When to Seek Urgent Help

Go to A&E or call emergency services if:

• You have thoughts of suicide or harming yourself
• You are making dangerous decisions during a "high" period
• You cannot care for yourself
• You are hearing or seeing things others cannot
• You haven't slept for several days

---

14. Viva Questions and Model Answers

Exam Detail: ### Q1: A 24-year-old medical student presents with reduced sleep (3 hours/night), increased energy, rapid speech, and has spent £10,000 on a business idea. What is your differential diagnosis and management approach?

Model Answer:

Differential Diagnosis (Structured):

Most Likely:

• Bipolar I Disorder - First Manic Episode (young age, classic presentation)
• Substance-induced mania (stimulants, cannabis - must exclude)

Important to Exclude:

• Drug intoxication (cocaine, amphetamines, novel psychoactive substances)
• Hyperthyroidism (can mimic mania)
• Corticosteroid-induced mania (medication history)
• Organic causes (frontal lobe pathology - unlikely but consider)

Immediate Management:

Assessment:

1. Full psychiatric assessment including MSE
2. Risk assessment - financial harm already occurred, assess for aggression, sexual disinhibition
3. Collateral history from family/friends essential
4. Capacity assessment - likely impaired

Investigations:

• Urine drug screen (essential)
• TFTs, FBC, U&Es, LFTs, glucose, lipids
• ECG (baseline before antipsychotic)

Setting:

• Almost certainly requires inpatient admission
• If refusing and lacks capacity with risks present - consider Mental Health Act assessment

Pharmacological:

• First-line: Atypical antipsychotic (e.g., olanzapine 10-15mg, risperidone 3-4mg)
• Consider benzodiazepine for acute agitation (lorazepam 1-2mg PRN)
• Initiate mood stabiliser (lithium) once acute episode settling

Psychosocial:

• Engage family, protect finances
• Psychoeducation once receptive
• Plan for occupational health regarding medical studies

Q2: Discuss the evidence for lithium in bipolar disorder and outline your monitoring protocol.

Model Answer:

Evidence Base:

Acute Mania:

• Moderate efficacy, slower onset than antipsychotics
• Often used in combination for severe mania

Maintenance/Prophylaxis:

• BALANCE trial (Lancet 2010) [3]: Lithium monotherapy superior to valproate monotherapy for relapse prevention in Bipolar I
• Meta-analyses confirm efficacy for preventing both manic and depressive episodes
• Evidence strongest for preventing manic relapse

Anti-suicidal Effect:

• Unique among mood stabilisers
• Cipriani meta-analysis (2013) [5]: 60-80% reduction in suicide risk
• Reduces suicide attempts and completed suicides
• Mechanism: May be related to serotonergic effects, impulse control

Neuroprotective Properties:

• Increases grey matter volume on MRI
• Anti-inflammatory and antioxidant effects
• GSK-3β inhibition promotes neuroplasticity

Monitoring Protocol:

Pre-Treatment:

• U&Es, eGFR, TFTs (TSH, fT4)
• Calcium (baseline)
• ECG (if cardiac history or age > 65)
• Weight, BMI
• Pregnancy test (women of childbearing potential)

Initiation Phase:

• Check lithium level 12 hours post-dose
• First level 5-7 days after starting
• Repeat weekly until stable in therapeutic range

Target Levels:

• Acute treatment: 0.8-1.0 mmol/L
• Maintenance: 0.6-0.8 mmol/L
• Elderly: 0.4-0.6 mmol/L (lower threshold)

Stable Maintenance:

• Lithium levels every 3 months (first year), then 6-monthly
• TFTs every 6 months
• U&Es, eGFR every 6 months
• Calcium annually
• Weight at each review

Special Circumstances:

• Check level if unwell (dehydration, infection)
• Review before any new medication (NSAIDs, ACE-I, diuretics)
• Patient education about toxicity symptoms

Q3: Compare and contrast the mood stabilisers available for bipolar disorder maintenance.

Model Answer:

Selection Guidance:

• Predominantly manic: Lithium first-line, valproate alternative (not in WOCBP)
• Predominantly depressive: Lamotrigine first-line, quetiapine alternative
• Mixed polarity: Combination approach often needed
• Women of childbearing potential: Avoid valproate; lamotrigine preferred
• Suicide risk prominent: Lithium has unique anti-suicidal effect

Q4: A 32-year-old woman with Bipolar II disorder wants to conceive. She is currently stable on valproate 1000mg daily. How would you counsel and manage her?

Model Answer:

Key Issues:

1. Valproate is absolutely contraindicated in pregnancy - must be changed
2. Risk of relapse during medication switch
3. Pregnancy and postpartum are high-risk periods for mood episodes
4. Need for multidisciplinary planning

Counselling Points:

Teratogenicity of Valproate:

• Neural tube defects (spina bifida): 1-2% risk (10-fold increase)
• Developmental delay: Affects 30-40% of exposed children
• Lower IQ: Average 10-point reduction in children exposed in utero
• Autism spectrum: 3-4 fold increased risk
• MHRA: Valproate should NOT be used in women of childbearing potential unless Pregnancy Prevention Programme followed

Pre-conception Planning:

• Ideally switch medications BEFORE conception (3-6 months before)
• Switch to safer alternative while not pregnant
• Ensure stable on new regimen before conceiving
• High-dose folic acid (5mg) recommended

Medication Options:

Recommended Approach:

1. Cross-taper from valproate to lamotrigine over 4-6 weeks
2. Titrate lamotrigine slowly (standard protocol)
3. Aim for stable period of 3-6 months before conception
4. Continue lamotrigine in pregnancy (dose may need adjustment)
5. Close psychiatric monitoring throughout pregnancy
6. Plan for postpartum - highest risk period; consider prophylactic measures
7. Discuss breastfeeding options (lamotrigine present in breast milk but often continued)

Postpartum Planning:

• 100-fold increased risk of postpartum psychosis in bipolar disorder
• Consider prophylactic lithium immediately postpartum
• Ensure sleep protection (partner feeds at night if possible)
• Close monitoring first 3 months

Q5: Describe the mechanism of action of lithium and explain why it is effective as a mood stabiliser.

Model Answer:

Proposed Mechanisms of Action:

Lithium's mechanism is complex and multifactorial, which may explain its broad therapeutic effects:

1. Inositol Depletion Hypothesis:

• Lithium inhibits inositol monophosphatase (IMPase)
• Reduces inositol recycling, depleting phosphatidylinositol (PI) signalling
• PI pathway is overactive in mania
• This dampens excessive neuronal signalling

2. Glycogen Synthase Kinase-3β (GSK-3β) Inhibition:

• GSK-3β is involved in multiple cellular processes
• Inhibition promotes neuroplasticity and neuroprotection
• Increases BDNF expression
• May underlie anti-apoptotic effects
• Shared mechanism with valproate

3. Protein Kinase C (PKC) Modulation:

• PKC activity elevated in mania
• Lithium reduces PKC activity
• Affects downstream signalling cascades

4. Neurotransmitter Effects:

• Modulates dopaminergic, serotonergic, and glutamatergic transmission
• Reduces dopamine receptor supersensitivity
• Increases serotonin synthesis and release
• Modulates NMDA receptor function

5. Circadian Rhythm Stabilisation:

• Acts on clock genes (CLOCK, BMAL1)
• Lengthens circadian period
• May stabilise sleep-wake cycles

6. Neuroprotective Properties:

• Increases grey matter volume (MRI studies)
• Promotes neurogenesis in hippocampus
• Anti-inflammatory and antioxidant effects
• Reduces mitochondrial dysfunction

7. Anti-Suicidal Effect (Unique):

• Mechanism unclear but may relate to:
  • Serotonergic enhancement
  • Reduced impulsivity
  • Anti-aggressive properties
  • Not simply due to mood stabilisation

Clinical Implications:

• Multiple mechanisms explain broad spectrum of effects
• Slow onset (days to weeks) consistent with intracellular changes
• Neuroprotection supports early and continuous treatment
• Narrow therapeutic index requires careful monitoring

Q6: A patient with bipolar disorder has had 5 mood episodes in the past 12 months despite lithium treatment. How would you approach this?

Model Answer:

Defining the Problem:

• This patient has rapid cycling (≥4 episodes in 12 months)
• Currently on lithium monotherapy which is inadequate
• Need to identify contributing factors and optimise treatment

Systematic Assessment:

1. Verify Diagnosis:

• Confirm episodes meet criteria (not just mood variability)
• Consider borderline personality disorder overlap
• Review longitudinal course with mood charts

2. Assess Lithium Treatment:

• Check adherence (plasma levels)
• Are levels therapeutic? (0.6-0.8 mmol/L for maintenance)
• Duration of adequate trial?

3. Identify Perpetuating Factors:

Treatment Strategies:

Step 1 - Optimise Current Treatment:

• Maximise lithium dose (if tolerated) to level 0.8-1.0 mmol/L
• Ensure thyroid is optimised
• Stop antidepressants (very important in rapid cycling)

Step 2 - Consider Alternative/Adjunctive Mood Stabiliser:

• Valproate: Often preferred in rapid cycling (not in WOCBP)
• Lamotrigine: Add for depressive pole prevention
• Combination lithium + valproate or lithium + lamotrigine

Step 3 - Add Atypical Antipsychotic:

• Quetiapine, olanzapine, aripiprazole all have maintenance indications
• Provides additional stabilisation

Step 4 - Treatment-Resistant Options:

• Clozapine (limited evidence but sometimes effective)
• ECT (particularly for depressive episodes)
• Thyroid augmentation (T3/T4 even if euthyroid)

Prognosis:

• Rapid cycling often not permanent - may remit
• Overall prognosis generally poorer
• Early identification and aggressive treatment important

Q7: What are the indications for ECT in bipolar disorder and what is the evidence?

Model Answer:

Indications for ECT in Bipolar Disorder:

Absolute/Strong Indications:

1. Severe bipolar depression with psychotic features
2. Life-threatening food/fluid refusal
3. Catatonia (either phase)
4. High suicide risk with need for rapid response
5. Treatment-resistant depression (failed multiple medications)

Relative Indications:

1. Severe mania refractory to pharmacotherapy
2. Mixed states with high risk
3. Pregnancy (safer than many medications)
4. Patient preference (prior good response)
5. Medical comorbidities limiting medication options

Evidence Base:

Bipolar Depression:

• Response rates: 50-70% in treatment-resistant cases
• Faster onset than medication (1-2 weeks vs 4-6 weeks)
• Particularly effective with psychotic features
• Comparable to unipolar depression response rates

Mania:

• Historically used, less common now with effective pharmacotherapy
• Response rates ~80% in case series
• Useful for catatonic mania
• May be faster than medication

Maintenance ECT:

• Some patients require ongoing ECT to maintain remission
• Typically monthly sessions
• Evidence limited but clinical experience supportive

Practical Considerations:

Cognitive Side Effects:

• Transient confusion post-treatment
• Anterograde amnesia (usually temporary)
• Retrograde amnesia (variable, usually improves)
• Bilateral > unilateral for cognitive effects

---

16. MCQ Practice Questions

Exam Detail: ### MCQ 1 A 28-year-old man presents with 5 days of elevated mood, decreased sleep (3 hours/night), increased energy, and has made several impulsive purchases totalling £15,000. He has pressured speech and believes he has special abilities. His urine drug screen is negative. What is the MOST appropriate first-line acute treatment?

A. Lithium monotherapy B. Fluoxetine C. Olanzapine D. Lamotrigine E. Cognitive behavioural therapy

Answer: C - Olanzapine

Explanation: This patient meets criteria for acute mania (elevated mood ≥7 days with functional impairment and grandiosity, decreased sleep, pressured speech, impulsivity). First-line acute treatment for mania is an atypical antipsychotic (olanzapine, risperidone, quetiapine, or aripiprazole) due to rapid onset of action. Lithium (A) is effective but has slower onset and is better for maintenance. Fluoxetine (B) - antidepressant monotherapy is contraindicated in bipolar as it can worsen mania. Lamotrigine (D) is for bipolar depression prevention, not acute mania. CBT (E) is adjunctive, not acute treatment for severe mania.

MCQ 2

A 35-year-old woman with Bipolar I disorder has been stable on lithium for 2 years. She wants to become pregnant. Which of the following statements about lithium in pregnancy is CORRECT?

A. Lithium is absolutely contraindicated in pregnancy B. The risk of Ebstein's anomaly is approximately 10% C. Lithium levels should be checked more frequently during pregnancy D. Lithium should be stopped immediately upon discovering pregnancy E. Breastfeeding is absolutely contraindicated with lithium

Answer: C - Lithium levels should be checked more frequently during pregnancy

Explanation: During pregnancy, renal clearance increases significantly, causing lithium levels to fall. Levels should be monitored monthly during pregnancy and more frequently near term. Lithium is NOT absolutely contraindicated (A) - the decision is individualised based on risk of relapse vs teratogenicity. The Ebstein's anomaly risk (B) was historically overestimated; current data suggest 0.1-0.5% (still elevated but much lower than 10%). Abrupt discontinuation (D) risks relapse; if stopping is planned, gradual taper is preferred. Breastfeeding (E) is not absolutely contraindicated; lithium does pass into breast milk, but with monitoring, some women choose to continue.

MCQ 3

Which of the following medications has the strongest evidence for PREVENTING DEPRESSIVE episodes in bipolar disorder?

A. Lithium B. Valproate C. Lamotrigine D. Haloperidol E. Carbamazepine

Answer: C - Lamotrigine

Explanation: Lamotrigine has the strongest evidence specifically for prevention of depressive episodes in bipolar disorder, with landmark trials (Calabrese et al.) demonstrating efficacy for depressive relapse prevention. Lithium (A) has good evidence for both poles but stronger for manic prevention. Valproate (B) is primarily effective for manic prevention. Haloperidol (D) is for acute mania, not maintenance. Carbamazepine (E) has evidence for maintenance but is less commonly used due to drug interactions and side effects.

MCQ 4

A patient with bipolar disorder on lithium presents with coarse tremor, vomiting, and confusion. His lithium level is 2.8 mmol/L. What is the MOST important immediate management?

A. Increase fluid intake orally B. Administer activated charcoal C. Arrange urgent haemodialysis D. Administer sodium bicarbonate E. Reduce lithium dose and recheck level

Answer: C - Arrange urgent haemodialysis

Explanation: This patient has severe lithium toxicity (> 2.5 mmol/L with neurological symptoms). At this level with significant symptoms, haemodialysis is indicated for rapid lithium removal. Oral fluids (A) are insufficient for severe toxicity. Activated charcoal (B) does not bind lithium effectively. Sodium bicarbonate (D) is not indicated. Simply reducing the dose (E) is completely inadequate - this is a medical emergency requiring dialysis and likely ITU admission.

MCQ 5

A 22-year-old woman with newly diagnosed Bipolar II disorder asks about medication options. She is sexually active and uses unreliable contraception. Which medication is MOST appropriate?

A. Valproate B. Carbamazepine C. Lamotrigine D. Lithium E. Topiramate

Answer: C - Lamotrigine

Explanation: For a woman of childbearing potential, valproate (A) is contraindicated due to severe teratogenicity (neural tube defects, developmental delay). Carbamazepine (B) also carries teratogenic risk. Lamotrigine (C) has the best safety profile in pregnancy among mood stabilisers and is particularly effective for Bipolar II (predominantly depressive). Lithium (D) carries moderate risk (Ebstein's anomaly) and would be second choice. Topiramate (E) is not a first-line mood stabiliser and has teratogenic concerns (cleft palate).

---

17. Clinical Case Scenarios

Exam Detail: ### Case 1: First Presentation Mania

Presentation: A 19-year-old university student is brought to A&E by police after being found directing traffic at 3am, wearing minimal clothing. His flatmates report he hasn't slept for 4 days, has been spending excessively online, and believes he has discovered the secret to unlimited energy. He has no psychiatric history but his father has "mood problems."

Questions:

Q1: What is the most likely diagnosis?

Bipolar I Disorder - First Manic Episode. The presentation shows:

• Elevated/expansive mood
• Severely decreased sleep (4 days)
• Grandiose delusions (secret to unlimited energy)
• Impulsive behaviour (spending)
• Disinhibition (directing traffic, minimal clothing)
• Family history of mood disorder
• Young age of onset (typical for bipolar)

Q2: What investigations would you request?

• Urine drug screen (essential - stimulants can mimic mania)
• FBC, U&Es, LFTs (baseline and exclude organic)
• TFTs (hyperthyroidism can cause mania-like symptoms)
• Glucose, lipids (baseline for medications)
• ECG (baseline before antipsychotics)
• Consider MRI brain if any atypical features

Q3: How would you manage this patient?

• Likely requires admission (high risk, lacks insight)
• If refusing - consider Mental Health Act assessment
• Start atypical antipsychotic (e.g., olanzapine 10mg, risperidone 2-3mg)
• Consider short-term benzodiazepine for agitation/insomnia
• Once acute episode settling, discuss lithium for maintenance
• Psychoeducation for patient and family
• Occupational considerations (university suspension)

Case 2: Bipolar Depression

Presentation: A 45-year-old woman presents with 6 weeks of low mood, anhedonia, hypersomnia (12 hours/day), weight gain, and passive suicidal ideation. She has had three previous "high" periods in her 20s and 30s where she felt extremely energetic, needed little sleep, and made impulsive career changes. Her GP started fluoxetine 2 weeks ago with no improvement.

Questions:

Q1: What is the likely diagnosis and what has been missed?

Bipolar II Disorder - current depressive episode. The previous "high" periods with decreased sleep need, increased energy, and impulsive behaviour (career changes) suggest hypomanic episodes. This has been misdiagnosed as unipolar depression.

Q2: What is the concern with current treatment?

Antidepressant monotherapy (fluoxetine) in bipolar disorder carries risks:

• Manic/hypomanic switch (20-40%)
• Induction of rapid cycling
• Worsening of mixed features
• The fluoxetine should be stopped or covered with a mood stabiliser

Q3: What treatment would you recommend?

First-line options for bipolar depression:

• Quetiapine monotherapy (strongest evidence)
• Lurasidone (with or without lithium/valproate)
• Lamotrigine (slower onset but good prophylaxis)
• Olanzapine-fluoxetine combination
• Stop fluoxetine monotherapy
• Assess suicide risk carefully (passive ideation present)

Case 3: Lithium Toxicity

Presentation: A 58-year-old man with Bipolar I disorder on lithium 800mg daily presents with 3 days of diarrhoea and vomiting following a viral gastroenteritis. He continued taking his lithium. He now has coarse tremor, ataxia, and confusion. His lithium level is 2.1 mmol/L.

Questions:

Q1: What is the diagnosis and precipitating factor?

Moderate-severe lithium toxicity precipitated by dehydration from gastroenteritis. Lithium is renally excreted; dehydration reduces clearance and causes accumulation.

Q2: What are the signs of lithium toxicity at different levels?

Q3: How would you manage this patient?

• Stop lithium immediately
• IV fluid resuscitation
• Cardiac monitoring
• Check U&Es urgently (hypokalaemia common)
• Repeat lithium level in 4-6 hours
• At 2.1 mmol/L with significant symptoms - consider haemodialysis
• ITU referral if neurological symptoms worsening
• Patient education on prevention when recovered

---

15. References

1. Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008. doi:10.1038/nrdp.2018.8 PMID: 29516993

2. Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241-251. doi:10.1001/archgenpsychiatry.2011.12 PMID: 21383262

3. BALANCE investigators and collaborators, Geddes JR, Goodwin GM, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010;375(9712):385-395. doi:10.1016/S0140-6736(09)61828-6 PMID: 20092882

4. Goodwin GM, Haddad PM, Ferrier IN, et al. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2016;30(6):495-553. doi:10.1177/0269881116636545 PMID: 26979387

5. Cipriani A, Hawton K, Stockton S, Geddes JR. Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis. BMJ. 2013;346:f3646. doi:10.1136/bmj.f3646 PMID: 23814104

6. NICE. Bipolar disorder: assessment and management. Clinical guideline [CG185]. 2014 (Updated 2023). Available at: https://www.nice.org.uk/guidance/cg185

7. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003;64(9):1013-1024. doi:10.4088/jcp.v64n0906 PMID: 14628976

8. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162(7):1351-1360. doi:10.1176/appi.ajp.162.7.1351 PMID: 15994719

9. Kupka RW, Luckenbaugh DA, Post RM, et al. Comparison of rapid-cycling and non-rapid-cycling bipolar disorder based on prospective mood ratings in 539 outpatients. Am J Psychiatry. 2005;162(7):1273-1280. doi:10.1176/appi.ajp.162.7.1273 PMID: 15994709

10. Berk M, Kapczinski F, Andreazza AC, et al. Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev. 2011;35(3):804-817. doi:10.1016/j.neubiorev.2010.10.001 PMID: 20934453

11. Sachs GS, Nierenberg AA, Calabrese JR, et al. Effectiveness of adjunctive antidepressant treatment for bipolar depression. N Engl J Med. 2007;356(17):1711-1722. doi:10.1056/NEJMoa064135 PMID: 17392295

12. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163(2):247-256. doi:10.1176/appi.ajp.163.2.247 PMID: 16449478

13. Yatham LN, Kennedy SH, Parikh SV, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97-170. doi:10.1111/bdi.12609 PMID: 29536616

14. McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012;379(9817):721-728. doi:10.1016/S0140-6736(11)61516-X PMID: 22265699

15. Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160-168. doi:10.1176/appi.ajp.2013.13070984 PMID: 24170180

16. Fountoulakis KN, Vieta E. Treatment of bipolar disorder: a systematic review of available data and clinical perspectives. Int J Neuropsychopharmacol. 2008;11(7):999-1029. doi:10.1017/S1461145708009231 PMID: 18752718

17. Grande I, Berk M, Birmaher B, Vieta E. Bipolar disorder. Lancet. 2016;387(10027):1561-1572. doi:10.1016/S0140-6736(15)00241-X PMID: 26388529

18. Miklowitz DJ, Efthimiou O, Furukawa TA, et al. Adjunctive psychotherapy for bipolar disorder: a systematic review and component network meta-analysis. JAMA Psychiatry. 2021;78(2):141-150. doi:10.1001/jamapsychiatry.2020.2993 PMID: 33052390

19. Post RM, Denicoff KD, Leverich GS, et al. Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry. 2003;64(6):680-690. doi:10.4088/jcp.v64n0610 PMID: 12823083

20. Bowden CL, Calabrese JR, McElroy SL, et al. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch Gen Psychiatry. 2000;57(5):481-489. doi:10.1001/archpsyc.57.5.481 PMID: 10807488

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. It does not replace professional medical judgement. Always consult relevant guidelines and consider individual patient factors when making clinical decisions.